This Forum brings together forward-thinking investors and a hand-selected group of high-potential startups for focused, insight-driven presentations.
Each company delivers a 5-minute presentation with Q&A, designed to surface meaningful discussion, validate opportunity, and accelerate engagement.
The program also features updates from select alumni companies, offering a clear view into post-Forum progress, milestones achieved, and future direction.
Where innovation meets traction—and relationships turn into outcomes.
TBD
ClearSight Therapeutics is commercializing a first-in-class ocular surface protection platform designed to transform OTC eye care. With exclusive access to a critical supply chain, $84 million in contracted demand, and established distribution partners secured before launch, ClearSight offers a rare combination of innovation, commercial validation, and capital-efficient growth.
Engraft Technologies is commercializing the first fully closed-loop robotic hair transplant system, cutting surgery time from 10 hours to under 3 and halving required staff. Founded by the pioneers of FUE and NeoGraft, and protected by five US patents, we're targeting a $10 billion market with no dominant player.
OmniPad is the world's only patented, circular revolving-tread, omnidirectional human locomotion system. It combines virtual reality with cardiovascular exercise and rehabilitation, industrial and military training and much more.
TRUE-See has built the trusted standard for medical photography by enabling verifiably accurate and certified authentic clinical images that support better care, reliable data, regulatory confidence, and AI. Its platform ensures every medical image can be trusted for documentation, decision-making, and evidence generation.
Exactice Medical is developing the AIM™ device, a patented breakthrough technology designed to make transseptal cardiac procedures faster, safer, and more efficient by integrating real-time imaging with a steerable access needle into a single device. Targeting a rapidly growing multibillion-dollar market, Exactice combines strong clinical validation, experienced leadership, and significant strategic acquisition potential.